Cannabis-Related treatment demands in Belgium: a socio-demographic and treatment seeking profile

Archives of Public Health

K Colpaert²  W Vanderplasschen²  G Van Hal¹  G Schuyten³  E Broekaert² 

[1] University of Antwerp, University Scientific Institute for Drug Problems

[2] Ghent University, Department of Orthopedagogics

[3] Ghent University, Department of Data-analysis

关键词: Demographics;    Drug Use;    Substance Abuse Treatment;    Treatment Demand;    Cannabis;   

Others  :  1083916
DOI  :  10.1186/0778-7367-67-4-179

【 摘 要 】

Aims

Most people appear to stop using cannabis when getting older, but a certain subgroup becomes cannabis dependent, has problems in various life areas and needs treatment. Our aim is to compare a number of sociodemographic and treatment seeking variables between treatment seekers with primary cannabis problems and those with primary alcohol, opiate, amphetamine or cocaine problems. Understanding how primary canna-bis users seeking treatment differ from other treatment seekers may assist clinicians in better tailoring treatment processes to clients' needs.

Methods

For this purpose, intake information on 1,626 persons seeking treatment in one of 16 treat-ment agencies in the province of Antwerp (Belgium) was registered via an on-line web application. Primary cannabis users seeking treatment were compared with primary alcohol, opiate, amphetamine and cocaine users by means of bivariate analyses (Chi-square tests and analyses of variance), followed by four logistic regression analyses.

Findings

14.5% of all clients used cannabis as their primary drug. Compared to primary alcohol, opiate, amphetamine or cocaine users seeking treatment, cannabis users seeking treatment appeared to be more often male, younger than 30 years old, Belgian and student. They are often referred to treatment by police or justice and 43.6% of them can be considered single-substance users. Multivariate analyses showed that besides age and sex, using no other substances than the primary drug and being registered in outpatient facilities only were significant determinants for being a primary cannabis user seeking treatment.

Conclusions

Primary cannabis users can clearly be differentiated from other drug users seeking treatment. Although cannabis plays an important part in a polydrug use pattern, persons who have cannabis as their primary drug often use only this one substance. Since they regularly have brief contacts with treatment agencies, more research is needed to measure the effect of this brief intervention.

【 授权许可】

   
2010 Colpaert et al.

【 参考文献 】

• [1]European Monitoring Centre on Drugs and Drug Addiction (EMCDDA): Annual report 2007: the state of the drugs problem in Europe. EMCDDA: Lisboa; 2007.
• [2]Substance Abuse and Mental Health Administration (SAMHSA): 2005 National Survey on Drug Use and Health. SAMHSA: Rockville MD; 2006.
• [3]Agosti V, Levin FR: Predictors of Cannabis Dependence Recovery Among Epidemiological Survey Respondents in the United States. Am J Drug Alcohol Abuse 2007, 33:81-8.
• [4]Chen K, Kandel DB: Predictors of cessation of marijuana use: An event history analysis. Drug Alcohol Depend 1998, 50:109-51.
• [5]von Sydow K, Lieb R, Pfister H, Hofler M, Sonntag H, Wittchen HU: The natural course of cannabis use, abuse and dependence over four years: a longitudinal community study of adolescents and young adults. Drug Alcohol Depend 2001, 64:347-61.
• [6]Terry P, Wright KA, Cochrane R: Factors contributing to changes in frequency of cannabis consumption by cannabis users in England: A structured interview study. Addict Res Theory 2007, 15:113-119.
• [7]Kalant H: Adverse effects of cannabis on health: an update of the literature since 1996. Prog Neuropsychopharmacol 2004, 28:849-63.
• [8]Kokkevi A, Gabhainn S, Spyropoulo M: Early Initiation of Cannabis Use: A Cross-national European Perspective. J Adolesc Health 2006, 39:712-9.
• [9]Chen CY, O'Brien MS, Anthony JC: Who becomes cannabis dependent soon after onset of use? Epidemiological evidence from the United States: 2000-2001. Drug Alcohol Depend 2005, 79:11-22.
• [10]Wagner FA, Anthony JC: Into the world of illegal drug use: Exposure opportunity and other mechanisms linking the use of alcohol, tobacco, marijuana, and cocaine. Am J Epidemiol 2002, 155:918-25.
• [11]Hall W, Solowij N, Lemon J: The health and psychological consequences of cannabis use. Australian Government Publishing Service (National Drug Strategy Monograph Series No 25): Canberra. 1994.
• [12]Compton WM, Grant BF, Colliver JD, Glantz MD, Stinson FS: Prevalence of Marijuana Use Disorders in the United States. 1991-1992 and 2001-2002. JAMA 2004, 291:2114-21.
• [13]Agosti V, Levin FR: Predictors of Treatment Contact Among Individuals with Cannabis Dependence. Am J Drug Alcohol Abuse 2004, 30:121-7.
• [14]Stinson FS, Ruan WJ, Pickering R, Grant BF: Cannabis use disorders in the USA: prevalence, correlates and co-morbidity. Psychol Med 2006, 36:1447-60.
• [15]Substance Abuse and Mental Health Administration (SAMHSA): 2006 Treatment Episode Data Set. National Admissions to Substance Abuse Treatment Services. SAMHSA: Rockville MD; 2007.
• [16]Budney AJ, Radonovich KJ, Higgins ST, Wong CJ: Adults Seeking Treatment for Marijuana Dependence: A Comparison With Cocaine-Dependent Treatment Seekers. Exp Clin Psychopharmacol 1998, 6:419-26.
• [17]Stephens RS, Roffman RA, Simpson EE: Adult Marijuana Users Seeking Treatment. J Consult Clin Psychol 1993, 61:1100-04.
• [18]Tims FM, Dennis ML, Hamilton N, Buchan BJ, Diamond G, Funk R, et al.: Characteristics and problems of 600 adolescent cannabis abusers in outpatient treatment. Addiction 2002, 97:46-57.
• [19]Urbanoski KA, Strike CJ, Rush BR: Individuals Seeking Treatment for Cannabis-Related Problems in Ontario: Demographic and Treatment Profile. Eur Addict Res 2005, 11:115-23.
• [20]Copeland J, Swift W, Rees V: Clinical profile of participants in a brief intervention program for cannabis use disorder. J Subst Abuse Treat 2001, 20:45-52.
• [21]Nordstrom BR, Levin FR: Treatment of Cannabis Use Disorders: A Review of the Literature. Am J Addict 2007, 16:331-42.
• [22]Vanderplasschen W, Colpaert K, Broekaert Eric: Determinants of relapse and re-admission among alcohol abusers after intensive residential treatment. Arch Public Health 2009, 67(4):194-211.
• [23]Simon R, Donmall M, Hartnoll R, Kokkevi A, Ouwehand AW, Stauffacher M, Vicente J: The EMCDDA/Pompidou Group Treatment Demand Indicator Protocol: A European core item set for treatment monitoring and reporting. Eur Addict Res 1999, 5:197-207.
• [24]Soldz S, Panas L, Rodriguez-Howard M: The Reliability of the Massachusetts Substance Abuse Management Information System. J Clin Psychol 2002, 58:1057-69.
• [25]Colpaert K, Vanderplasschen W, Van Hal G, Broekaert E, Schuyten G: Dual substance abusers demanding treatment: demographic, substance-related and treatment utilization characteristics. J Drug Issues 2008, 38:559-83.
• [26]Stauffacher M, Kokkevi A: The Pompidou Group treatment demand protocol: The first pan-European standard in the field. Eur Addict Res 1999, 5:191-6.
• [27]Colpaert K, De Clercq T: Implementing the « Treatment Demand Indicator » in Belgium: registration of drug users in treatment. In IPH/IHE REPORTS Nr 2003-018. Scientific Institute of Public Health (Epidemiology Unit): Brussels; 2003.
• [28]Kokkevi A, Hartgers C: EuropASI: European adaptation of a multidimensional assessment instrument for drug and alcohol dependence. Eur Addict Res 1995, 1:194-8.
• [29]Raes V, Lombaert G, Keymeulen R: De nederlandse vertaling van de handleiding voor training en afname van EuropASI vraaggesprekken, aangepast voor België Vlaanderen, met integratie van de Treatment Demand Indicator. Gent, De Sleutel Dienst Wetenschappelijk Onderzoek 2008.
• [30]Hartnoll R: Systèmes de déclaration de traitement pour consommation de drogues et indicateur première demande de traitement. Conseil de l'Europe: Strasbourg 1994.
• [31]ElSohly MA, Ross SA, Mehmedic Z, Arafat R, Yi B, Banahan BF: Potency-trends of delta9-THC and other cannabinoids in confiscated marijuana from 1980-1997. J Forensic Sci 2000, 45:24-30.
• [32]Licata M, Verri P, Beduschi G: Delta9-THC content in illicit cannabis products over the period 1997-2004 (first four months). Ann Ist Super Sanita 2005, 41:483-5.
• [33]Pijlman FTA, Rigter SM, Hoek J, Goldschmidt HMJ, Niesink RJM: Strong increase in total delta-THC in cannabis preparations sold in Dutch coffee shops. Addict Biol 2005, 10:171-80.
• [34]Mohler-Kuo M, Lee JE, Wechsler H: Trends in marijuana and other illicit drug use among college students: Results from 4 Harvard School of Public Health College Alcohol Study surveys: 1993-2001. J Am Coll Health 2003, 52:17-24.
• [35]O'Malley PM, Johnston LD: Epidemiology of alcohol and other drug use among American college students. J Stud Alcohol 2002, 14:23-39.
• [36]Van Hal G, Rosiers J, Bernaert I, Hoeck S: In hogere sferen? Een onderzoek naar het middelengebruik bij Antwerpse studenten. Universiteit Antwerpen: Antwerpen; 2007.
• [37]Caldeira KM, Arria AM, O'Grady KE, Vincent KB, Wish ED: The occurrence of cannabis use disorders and other cannabis-related problems among first-year college students. Addict Behav 2008, 33:397-411.
• [38]Klee H, Faugier J, Hayes C, Boulton T, Morris J: AIDS-related risk behaviour, polydrug use and temazepam. Brit J Addict 1990, 85:1125-32.
• [39]Van Hal G, Van Damme P, Van Cauwenberghe K: Vijftijen jaar registratie van geverbaliseerde druggebruikers in Vlaanderen en Brussel: 1990-2004. In ESOC Publicatie 42. Universiteit Antwerpen, Vakgroep Epidemiologie en Sociale Geneeskunde: Antwerpen; 2005.
• [40]European Monitoring Centre on Drugs and Drug Addiction (EMCDDA): Annual report 2006: the state of the drugs problem in Europe. EMCDDA: Lisboa; 2006.
• [41]Kaner EFS, Beyer F, Dickinson HO, Pienaar E, Campbell F, Schlesinger C, et al.: Effectiveness of brief alcohol interventions in primary care populations (review). Cochrane Database Sys Rev 2007. Art. No. CD004148 2007
• [42]Toumbourou JW, Stockwell T, Neighbors C, Marlatt GA, Sturge J, Rehm J: Adolescent Health 4 - Interventions to reduce harm associated with adolescent substance use. Lancet 2007, 369:1391-401.
• [43]Caetano R, Schafer J: DSM-IV alcohol dependence and drug abuse dependence in a treatment sample of Whites, Blacks and Mexican Americans. Drug Alcohol Depend 1996, 43:93-101.
• [44]Babor TF, Steinberg K, Anton R, Del Boca F: Talking is cheap. Measuring drinking outcomes in clinical trials. J Stud Alcohol 2000, 61:55-63.
• [45]Del Boca FK, Noll JA: Truth or consequences: the validity of self-report data in health services research on addictions. Addiction 2000, 95:S347-60.
• [46]Vitale SG, Van de Mheen D, Van de Wiel A, Garretsen HFL: Alcohol and illicit drug use among emergency room patients in The Netherlands. Alcohol Alcohol 2006, 41:553-9.
• [47]Martin CS, Clifford PR, Maisto SA, Earleywine M, Kirisci L, Longabaugh R: Polydrug use in an inpatient treatment sample of problem drinkers. Alcohol Clin Exp Res 1996, 20:413-7.
• [48]Callaghan RC, Brands B, Taylor L, Lentz T: The Clinical Characteristics of Adolescents Reporting Methamphetamine as Their Primary Drug of Choice: An Examination of Youth Admitted to Inpatient Substance-Abuse Treatment in Northern British Columbia, Canada, 2001-2005. J Adolesc Health 2007, 40:286-9.
• [49]Gossop M, Stephens S, Stewart D, Marshall J, Bearn J, Strang J: Health care professionals referred for treatment. Alcohol Alcohol 2001, 36:160-4.
• [50]Slesnick N, Bartle-Haring S, Glebova T, Glade A: Primary alcohol versus primary drug use among adolescents: an examination of differences. Addict Behav 2006, 31:2080-93.